AIkido Pharma Provides Update on its Antiviral Platform, Including the Virus That Causes COVID-19
AIkido Pharma Inc. (Nasdaq: AIKI) announced an update on its anti-viral platform targeting multiple viruses, including COVID-19 and influenza. Two lead compounds have been optimized for drug-like properties and will soon enter animal testing. A third compound has also been identified for optimization. Initial tests are focused on the Influenza virus, with SARS-CoV-2 testing planned shortly. The company emphasizes its use of AI technology in drug development, showcasing advancements in research.
- Two lead anti-viral compounds optimized for drug-like properties.
- Third lead compound identified and set for optimization.
- Target viruses include COVID-19, influenza, and Ebola.
- None.
NEW YORK, Feb. 22, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced an update on its broad spectrum anti-viral platform compounds with the potential to treat influenza, COVID-19, Ebola and other viral infections. The initial two lead compounds, which target the SKI complex in humans, have been optimized through the use of computer assisted learning, through two rounds of chemical modifications to achieve drug-like properties required to move the compounds into animal testing. In addition, a third lead compound has been identified and will be subjected to optimization. These new compounds are currently being tested against Influenza virus with testing on SARS-CoV-2 in the near future. Subsequently, the top analogs from each series of lead compounds will be selected for tests of their anti-viral effects in a SARS-CoV-2 mouse model.
Anthony Hayes, CEO of AIkido Pharma, stated, "We are excited to be using Artificial Intelligence technology to advance the development of these compounds and proud to announce these advancements in the research."
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Contact: | |
Investor Relations: | |
Hayden IR | |
Brett Maas, Managing Partner | |
Phone: (646) 536-7331 | |
Email: brett@haydenir.com | |
AIkido Pharma Inc.: | |
Phone: 212-745-1373 | |
Email: investorrelations@aikidopharma.com | |
View original content to download multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-provides-update-on-its-antiviral-platform-including-the-virus-that-causes-covid-19-301231899.html
SOURCE AIkido Pharma Inc.
